Table 4.
Week postquit day
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Condition | 1 | 2 | 4 | 6 | 8a | 12 | 16 | 24 | 32 | MPPb |
Missing data = smoking (n = 989) | ||||||||||
Placebo | .39 | .36 | .29 | .27 | .26 | .25 | .26 | .19 | .18 | .10 |
30 mg | .43 | .41 | .38* | .34 | .32 | .27 | .25 | .20 | .16 | .10 |
60 mg | .45 | .39 | .38* | .35 | .33 | .29 | .23 | .19 | .15 | .10 |
| ||||||||||
Incomplete treatment phase datac | ||||||||||
Placebo | .25 | .18 | .09 | .04 | ||||||
30 mg | .29 | .24 | .18 | .19 | ||||||
60 mg | .29 | .23 | .18 | .11 | ||||||
| ||||||||||
Complete treatment phase datad | ||||||||||
Placebo | .54 | .55 | .46 | .45 | .44 | |||||
30 mg | .59 | .60 | .60* | .58* | .54* | |||||
60 mg | .67* | .62 | 63* | .64* | .62* | |||||
| ||||||||||
Averaged resultse | ||||||||||
Placebo | .45 | .46 | .39 | .40 | .44 | |||||
30 mg | .49 | .50 | .51* | .53* | .54* | |||||
60 mg | .53 | .50 | .51* | .57* | .62* | |||||
| ||||||||||
End-of-treatment abstainersf | ||||||||||
Placebo | .92 | .96 | .90 | .91 | ||||||
30 mg | .83 | .84* | .91 | .83 | ||||||
60 mg | .85 | .80* | .81 | .86 |
End of treatment.
Multiple point prevalence (MPP) denoting verified abstinence at the 26-week follow-up and at all preceding intervals.
ns = 289, 222, 163, and 80, respectively.
ns = 570, 570, 568, 558, and 570, respectively.
ns = 859, 792, 731, 638, and 570, respectively.
ns = 281, 256, 210, and 180, respectively.
Different than placebo at p ≤ .05 by chi-square test.